Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Fulcrum Therapeutics, Inc. (FULC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics,"
05/15/2023 8-K Quarterly results
Docs: "Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics,"
03/09/2023 8-K Quarterly results
Docs: "Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics,"
11/08/2022 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
08/11/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Fulcrum Therapeutics ® Reports Recent Business Highlights and Third Quarter 2021 Financial Results – On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease –"
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results – ReDUX4 trial progressing; full data with losmapimod in facioscapulohumeral muscular dystrophy expected in 2Q 2021 –"
08/11/2020 8-K Quarterly results
Docs: "Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results – Conference call scheduled for 8:00 a.m. ET today –"
05/13/2020 8-K Quarterly results
03/05/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
08/26/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 26, 2019 Fulcrum Therapeutics, Inc. Delaware 001-38978 47-4839948 26 Landsdowne Street Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 651-8851 Not applicable",
"Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights - Completed initial public offering, raising $72.0 million in gross proceeds - - Initiated ReDUX4, a Phase 2b clinical trial of losmapimod in FSHD - - Initiated a Phase 2 open label clinical trial of losmapimod in FSHD - CAMBRIDGE, Mass. - Aug. 26, 2019 - Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the second quarter of 2019. “Over the second quarter we continued to make strides in advancing our pipeline, positioning us well for the completion of our initial public offering in July,” said Robert J. Gould, Ph.D., Fulcr..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy